We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Read MoreHide Full Article
Key Takeaways
Nkarta shares surged 15.7% after the FDA cleared key protocol changes for NKX019 autoimmune disease studies.
NKTX gains from outpatient dosing shift, cutting monitoring time and easing patient access.
NKTX adds re-dosing option and plans a rheumatoid arthritis cohort, expanding study scope and market reach.
Nkarta (NKTX - Free Report) shares surged 15.7% on Thursday, reflecting strong investor optimism following a meaningful regulatory update tied to its lead autoimmune program, NKX019, an investigational CAR-NK cell therapy. The rally was observed after NKTX reached an agreement with the FDA on key protocol changes that could materially improve study efficiency, patient accessibility and the therapy’s broader commercial potential.
Per Nkarta, the FDA has cleared amendments to its ongoing Ntrust-1 and Ntrust-2 studies, most notably enabling outpatient dosing of NKX019. This change significantly reduces monitoring requirements from 24 hours to just two, eliminating the need for overnight hospital stays. Management believes that such a shift could lower treatment burden, improve patient enrollment rates and expand administration into community rheumatology centers, thereby accelerating study execution and future scalability.
The FDA agreement also introduces greater clinical flexibility. Nkarta now has the option to re-dose patients in both studies, a move that could enhance therapeutic durability and optimize individual patient outcomes. In addition, the planned inclusion of a rheumatoid arthritis cohort in the Ntrust-2 study broadens NKX019’s addressable market into a high-prevalence autoimmune indication with high unmet need, signaling potential for significant pipeline expansion.
Investors also appear encouraged by upcoming catalysts, with initial clinical data from these studies expected to be presented at a medical meeting later this year. Taken together, the combination of reduced logistical barriers, expanded study scope and near-term data visibility likely underpinned the sharp upward move in Nkarta stock.
Year to date, NKTX stock has surged 51.3% compared with the industry’s 2.7% growth.
Image Source: Zacks Investment Research
More on NKTX’s NKX019 Studies for Autoimmune Diseases
Nkarta’s Ntrust-1 and Ntrust-2 are dose-escalation clinical studies designed to build on prior academic evidence showing durable, drug-free remissions in autoimmune diseases following CD19-targeted cell therapies. Both ongoing studies are primarily evaluating the safety profile of NKX019 while also assessing its potential to induce sustained remission via a “reset” of the immune system through the elimination of pathogenic B cells.
The studies are currently enrolling patients across a range of autoimmune indications, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. Rheumatoid arthritis is expected to be added as an additional cohort once the amended protocol receives final clearance, which would further expand the therapy’s target population.
Per the study design, patients receive a three-dose cycle of NKX019 administered on Days 0, 3 and 7, following lymphodepletion with fludarabine and cyclophosphamide or cyclophosphamide alone, if they have significant cytopenia at baseline. Notably, no supplemental cytokines or antibody-based therapies are used, allowing researchers to evaluate NKX019 as a single-agent treatment and potentially streamline its regulatory pathway. Patients may also receive additional treatment cycles, if needed, to deepen or restore therapeutic response.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have increased from $2.55 to $2.87. CPRX shares have gained 11% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ADMA Biologics’ 2026 EPS have increased from 85 cents to 93 cents. ADMA shares have plummeted 41.2% year to date.
ADMA Biologics’ earnings beat estimates in one of the trailing three quarters, matched once and missed on the remaining occasion, with the average negative surprise being 1.79%.
Over the past 60 days, estimates for Inovio Pharmaceuticals’ 2026 loss per share have narrowed from $1.26 to $1.06. INO shares have plunged 33.4% year to date.
Inovio Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 57.94%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Key Takeaways
Nkarta (NKTX - Free Report) shares surged 15.7% on Thursday, reflecting strong investor optimism following a meaningful regulatory update tied to its lead autoimmune program, NKX019, an investigational CAR-NK cell therapy. The rally was observed after NKTX reached an agreement with the FDA on key protocol changes that could materially improve study efficiency, patient accessibility and the therapy’s broader commercial potential.
Per Nkarta, the FDA has cleared amendments to its ongoing Ntrust-1 and Ntrust-2 studies, most notably enabling outpatient dosing of NKX019. This change significantly reduces monitoring requirements from 24 hours to just two, eliminating the need for overnight hospital stays. Management believes that such a shift could lower treatment burden, improve patient enrollment rates and expand administration into community rheumatology centers, thereby accelerating study execution and future scalability.
The FDA agreement also introduces greater clinical flexibility. Nkarta now has the option to re-dose patients in both studies, a move that could enhance therapeutic durability and optimize individual patient outcomes. In addition, the planned inclusion of a rheumatoid arthritis cohort in the Ntrust-2 study broadens NKX019’s addressable market into a high-prevalence autoimmune indication with high unmet need, signaling potential for significant pipeline expansion.
Investors also appear encouraged by upcoming catalysts, with initial clinical data from these studies expected to be presented at a medical meeting later this year. Taken together, the combination of reduced logistical barriers, expanded study scope and near-term data visibility likely underpinned the sharp upward move in Nkarta stock.
Year to date, NKTX stock has surged 51.3% compared with the industry’s 2.7% growth.
Image Source: Zacks Investment Research
More on NKTX’s NKX019 Studies for Autoimmune Diseases
Nkarta’s Ntrust-1 and Ntrust-2 are dose-escalation clinical studies designed to build on prior academic evidence showing durable, drug-free remissions in autoimmune diseases following CD19-targeted cell therapies. Both ongoing studies are primarily evaluating the safety profile of NKX019 while also assessing its potential to induce sustained remission via a “reset” of the immune system through the elimination of pathogenic B cells.
The studies are currently enrolling patients across a range of autoimmune indications, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. Rheumatoid arthritis is expected to be added as an additional cohort once the amended protocol receives final clearance, which would further expand the therapy’s target population.
Per the study design, patients receive a three-dose cycle of NKX019 administered on Days 0, 3 and 7, following lymphodepletion with fludarabine and cyclophosphamide or cyclophosphamide alone, if they have significant cytopenia at baseline. Notably, no supplemental cytokines or antibody-based therapies are used, allowing researchers to evaluate NKX019 as a single-agent treatment and potentially streamline its regulatory pathway. Patients may also receive additional treatment cycles, if needed, to deepen or restore therapeutic response.
Nkarta, Inc. Price and Consensus
Nkarta, Inc. price-consensus-chart | Nkarta, Inc. Quote
NKTX’s Zacks Rank and Stocks to Consider
Nkarta currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , ADMA Biologics (ADMA - Free Report) and Inovio Pharmaceuticals (INO - Free Report) . While CPRX and ADMA sport a Zacks Rank #1 (Strong Buy) each, INO carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have increased from $2.55 to $2.87. CPRX shares have gained 11% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ADMA Biologics’ 2026 EPS have increased from 85 cents to 93 cents. ADMA shares have plummeted 41.2% year to date.
ADMA Biologics’ earnings beat estimates in one of the trailing three quarters, matched once and missed on the remaining occasion, with the average negative surprise being 1.79%.
Over the past 60 days, estimates for Inovio Pharmaceuticals’ 2026 loss per share have narrowed from $1.26 to $1.06. INO shares have plunged 33.4% year to date.
Inovio Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 57.94%.